Stock Region Watchlist
The Tuesday Briefing: Hot Takes & Hard Numbers
The Tuesday Briefing: Hot Takes & Hard Numbers
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice. All investment involves risk. Past performance is not indicative of future results. Please consult a certified financial advisor before making any decisions.
Volatile morning, Stock Region family. The market is serving us a classic “good news, bad news” sandwich today. We have a retail giant stumbling on guidance, a gas station chain proving it’s actually a top-tier restaurant, and a biotech firm smashing a Phase 3 trial. Let’s break down the movers.
Kohl’s Corporation ($KSS) – The Retail Heartbreaker
Honestly, this one hurts to watch. Kohl’s did the hard part—they beat earnings estimates ($1.07 vs. $0.85), which usually triggers a rally. But the market hated the revenue miss ($5.0B) and the “cautious” 2026 outlook so much that they dumped the stock 10% pre-market. It feels like investors are ignoring the debt refinancing and balance sheet improvements in favor of panic over the top line.
The Silver Lining: A $0.125 dividend is coming (Ex-div: March 18).
Take: This screams “oversold,” but don’t try to catch a falling knife until it stabilizes.
Watch Levels: Resistance at $14.80, Support at $13.94.
Casey’s General Stores ($CASY) – The “Kitchen That Sells Gas”
We’ve said it before, and I’ll say it again: Casey’s is a pizza company disguised as a gas station. They absolutely crushed Q3 earnings ($3.49 vs. $3.01), and get this—same-store food sales are up 4.1%. Even with oil surging past $111, they are maintaining a massive 41-cent fuel margin. That is operational excellence, plain and simple.
Analyst Vibe: Stephens and KeyCorp are targeting $700.
Take: In an inflationary environment, people trade down from restaurants to convenience store food. Casey’s wins here. It’s a defensive beast.
Watch Levels: Resistance at $650.01, Support at $637.83.
Vertex Pharmaceuticals ($VRTX) – The Science Win
This is the kind of news we love. Vertex isn’t just the “Cystic Fibrosis company” anymore. Their new kidney disease drug (povetacicept) just aced its Phase 3 interim results, sending the stock up nearly 5%. They are rushing an FDA submission by the end of this month (March 2026). This effectively “de-risks” their entire non-CF pipeline.
Street Action: BMO raised their target to $600.
Take: When a biotech giant proves it has a second act, the multiple expansion can be huge. This feels like the start of a new leg up.
Watch Levels: Resistance at $495.00, Support at $482.46.
Disclaimer: The content of this newsletter is the personal opinion of the author and is not endorsed by Stock Region as financial advice. Trading stocks, especially around earnings and clinical trials, carries significant risk of loss. Do your own due diligence.